Catalyst Brief

← Calendar

Readoutin 45d

Biocad — BCD-217

Phase 3 primary completion: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma.

Date
Jan 2027
Type
Readout
Indication
Melanoma Stage III

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.